Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AQST NASDAQ:CMPX NASDAQ:CRBP NASDAQ:ITOS On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAQSTAquestive Therapeutics$5.42+7.1%$3.98$2.12▼$5.80$504.60M1.822.16 million shs6.06 million shsCMPXCompass Therapeutics$3.44+2.1%$3.01$1.27▼$4.08$466.01M1.51.40 million shs388,871 shsCRBPCorbus Pharmaceuticals$9.86-1.6%$8.93$4.64▼$56.93$120.83M3.0896,261 shs57,623 shsITOSiTeos Therapeutics$10.15$10.15$4.80▼$17.63$448.73M1.311.51 million shsN/A10 Best Stocks to Own: Fall 2025Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Fall 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAQSTAquestive Therapeutics+7.11%+43.77%+35.84%+52.25%+27.83%CMPXCompass Therapeutics+2.08%-1.43%+18.21%+37.60%+123.38%CRBPCorbus Pharmaceuticals-1.60%+5.23%+8.23%+6.83%-82.20%ITOSiTeos Therapeutics0.00%-0.82%+0.40%-0.20%-37.54%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAQSTAquestive Therapeutics$5.42+7.1%$3.98$2.12▼$5.80$504.60M1.822.16 million shs6.06 million shsCMPXCompass Therapeutics$3.44+2.1%$3.01$1.27▼$4.08$466.01M1.51.40 million shs388,871 shsCRBPCorbus Pharmaceuticals$9.86-1.6%$8.93$4.64▼$56.93$120.83M3.0896,261 shs57,623 shsITOSiTeos Therapeutics$10.15$10.15$4.80▼$17.63$448.73M1.311.51 million shsN/A10 Best Stocks to Own: Fall 2025Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Fall 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAQSTAquestive Therapeutics+7.11%+43.77%+35.84%+52.25%+27.83%CMPXCompass Therapeutics+2.08%-1.43%+18.21%+37.60%+123.38%CRBPCorbus Pharmaceuticals-1.60%+5.23%+8.23%+6.83%-82.20%ITOSiTeos Therapeutics0.00%-0.82%+0.40%-0.20%-37.54%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAQSTAquestive Therapeutics 3.00Buy$10.1487.14% UpsideCMPXCompass Therapeutics 3.10Buy$12.89274.68% UpsideCRBPCorbus Pharmaceuticals 3.10Buy$49.00396.96% UpsideITOSiTeos Therapeutics 2.14Hold$15.5052.71% UpsideCurrent Analyst Ratings BreakdownLatest CRBP, CMPX, AQST, and ITOS Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/3/2025AQSTAquestive TherapeuticsLifesci CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy8/13/2025AQSTAquestive TherapeuticsZacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong Sell ➝ Hold8/12/2025CMPXCompass TherapeuticsD. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$32.008/12/2025CMPXCompass TherapeuticsGuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$10.00 ➝ $12.008/7/2025ITOSiTeos TherapeuticsWells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetEqual Weight$12.00 ➝ $11.008/6/2025CRBPCorbus PharmaceuticalsOppenheimerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOutperform$56.00 ➝ $53.007/30/2025CRBPCorbus PharmaceuticalsB. RileySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy$28.007/21/2025ITOSiTeos TherapeuticsPiper SandlerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold7/21/2025ITOSiTeos TherapeuticsWedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform$12.00 ➝ $10.507/12/2025CRBPCorbus PharmaceuticalsLifesci CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy7/1/2025CMPXCompass TherapeuticsRaymond James FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeOutperform$9.00(Data available from 9/6/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAQSTAquestive Therapeutics$57.56M9.39N/AN/A($0.66) per share-8.21CMPXCompass Therapeutics$850K559.63N/AN/A$0.91 per share3.78CRBPCorbus PharmaceuticalsN/AN/AN/AN/A$11.69 per shareN/AITOSiTeos Therapeutics$35M12.82N/AN/A$11.17 per share0.91Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAQSTAquestive Therapeutics-$44.14M-$0.70N/AN/AN/A-147.38%N/A-63.87%11/3/2025 (Estimated)CMPXCompass Therapeutics-$49.38M-$0.45N/AN/AN/AN/A-53.11%-46.14%11/11/2025 (Estimated)CRBPCorbus Pharmaceuticals-$40.21M-$4.76N/AN/AN/AN/A-43.65%-39.62%11/6/2025 (Estimated)ITOSiTeos Therapeutics-$134.41M-$4.67N/AN/AN/AN/A-33.26%-28.16%11/11/2025 (Estimated)Latest CRBP, CMPX, AQST, and ITOS EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/11/2025Q2 2025AQSTAquestive Therapeutics-$0.18-$0.14+$0.04-$0.14$11.32 million$10.00 million8/11/2025Q2 2025CMPXCompass Therapeutics-$0.13-$0.14-$0.01-$0.14N/AN/A8/6/2025Q2 2025ITOSiTeos Therapeutics-$1.12-$1.51-$0.39-$1.81N/AN/A8/5/2025Q2 2025CRBPCorbus Pharmaceuticals-$1.55-$1.44+$0.11-$1.44N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAQSTAquestive TherapeuticsN/AN/AN/AN/AN/ACMPXCompass TherapeuticsN/AN/AN/AN/AN/ACRBPCorbus PharmaceuticalsN/AN/AN/AN/AN/AITOSiTeos TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAQSTAquestive TherapeuticsN/A3.533.18CMPXCompass TherapeuticsN/A7.667.66CRBPCorbus PharmaceuticalsN/A9.219.21ITOSiTeos TherapeuticsN/A7.537.53Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAQSTAquestive Therapeutics32.45%CMPXCompass Therapeutics68.43%CRBPCorbus Pharmaceuticals64.64%ITOSiTeos Therapeutics97.16%Insider OwnershipCompanyInsider OwnershipAQSTAquestive Therapeutics8.35%CMPXCompass Therapeutics29.80%CRBPCorbus Pharmaceuticals3.60%ITOSiTeos Therapeutics14.20%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAQSTAquestive Therapeutics16099.72 million91.40 millionOptionableCMPXCompass Therapeutics20138.28 million97.08 millionNot OptionableCRBPCorbus Pharmaceuticals4012.26 million11.81 millionOptionableITOSiTeos Therapeutics9044.21 million37.93 millionOptionableCRBP, CMPX, AQST, and ITOS HeadlinesRecent News About These CompaniesBVF Inc. IL Acquires 750,000 Shares of iTeos Therapeutics, Inc. $ITOSSeptember 5 at 7:56 AM | marketbeat.com683 Capital Management LLC Buys 831,883 Shares of iTeos Therapeutics, Inc. $ITOSSeptember 4 at 7:42 AM | marketbeat.comADAR1 Capital Management LLC Has $604,000 Position in iTeos Therapeutics, Inc. $ITOSSeptember 4 at 7:41 AM | marketbeat.comRA Capital Management L.P. Boosts Position in iTeos Therapeutics, Inc. $ITOSSeptember 4 at 7:02 AM | marketbeat.comHsbc Holdings PLC Has $458,000 Stake in iTeos Therapeutics, Inc. $ITOSSeptember 3 at 3:57 AM | marketbeat.comWellington Management Group LLP Has $837,000 Stock Holdings in iTeos Therapeutics, Inc. $ITOSSeptember 3 at 3:56 AM | marketbeat.comCharles Schwab Investment Management Inc. Increases Holdings in iTeos Therapeutics, Inc. $ITOSSeptember 3 at 3:18 AM | marketbeat.comDAFNA Capital Management LLC Has $1.27 Million Position in iTeos Therapeutics, Inc. $ITOSSeptember 1, 2025 | marketbeat.comNuveen LLC Invests $1.81 Million in iTeos Therapeutics, Inc. $ITOSSeptember 1, 2025 | marketbeat.comWall Street Zen Upgrades iTeos Therapeutics (NASDAQ:ITOS) to SellSeptember 1, 2025 | marketbeat.comiTeos Therapeutics (NASDAQ:ITOS) Upgraded to Sell at Wall Street ZenAugust 31, 2025 | americanbankingnews.comiTeos Therapeutics, Inc. (NASDAQ:ITOS) Given Consensus Rating of "Hold" by BrokeragesAugust 24, 2025 | marketbeat.comSHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates ITOS and KLG on Behalf of ShareholdersAugust 20, 2025 | prnewswire.comITEOS THERAPEUTICS INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of iTeos Therapeutics, Inc. - ITOSAugust 19, 2025 | globenewswire.comQ3 EPS Estimates for iTeos Therapeutics Increased by WedbushAugust 11, 2025 | marketbeat.comiTeos Therapeutics (NASDAQ:ITOS) Announces Quarterly Earnings Results, Misses Estimates By $0.39 EPSAugust 9, 2025 | marketbeat.comiTeos Therapeutics (NASDAQ:ITOS) Given New $11.00 Price Target at Wells Fargo & CompanyAugust 8, 2025 | marketbeat.comiTeos Therapeutics (ITOS) to Release Earnings on ThursdayAugust 7, 2025 | marketbeat.comiTeos Therapeutics accepts takeover bid from ConcentraJuly 23, 2025 | thepharmaletter.comTSHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates ITOS and ZIMV on Behalf of ShareholdersJuly 21, 2025 | globenewswire.comALERT: Rowley Law PLLC is Investigating Proposed Acquisition of iTeos Therapeutics, Inc.July 21, 2025 | prnewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCRBP, CMPX, AQST, and ITOS Company DescriptionsAquestive Therapeutics NASDAQ:AQST$5.42 +0.36 (+7.11%) Closing price 09/5/2025 04:00 PM EasternExtended Trading$5.40 -0.02 (-0.44%) As of 09/5/2025 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Aquestive Therapeutics, Inc. operates as a pharmaceutical company in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder. Its proprietary product candidates comprise Libervant, a buccal soluble film formulation of diazepam for the treatment of seizures; KYNMOBI, a sublingual film formulation of apomorphine for the treatment of episodic off-periods in Parkinson's disease; and Exservan, an oral soluble film formulation of riluzole for the treatment of amyotrophic lateral sclerosis. The company's proprietary pipeline of complex molecule product includes AQST-108, a sublingual film formulation delivering systemic epinephrine for the treatment of conditions other than anaphylaxis; and Anaphylm, an epinephrine sublingual film for the emergency treatment of allergic reactions, including anaphylaxis. In addition, it develops Adrenaverse, an epinephrine prodrug platform. The company was incorporated in 2004 and is headquartered in Warren, New Jersey.Compass Therapeutics NASDAQ:CMPX$3.44 +0.07 (+2.08%) Closing price 09/5/2025 04:00 PM EasternExtended Trading$3.44 +0.00 (+0.15%) As of 09/5/2025 05:26 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells. It also develops CTX-8371, a bispecific inhibitor that targets PD-1 and PD-L1 checkpoint inhibitor antibodies. The company was founded in 2014 and is headquartered in Boston, Massachusetts.Corbus Pharmaceuticals NASDAQ:CRBP$9.86 -0.16 (-1.60%) Closing price 09/5/2025 04:00 PM EasternExtended Trading$9.72 -0.14 (-1.41%) As of 09/5/2025 07:43 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Corbus Pharmaceuticals Holdings, Inc., a biopharmaceutical company, develops products to defeat serious illness. It develops CRB-701, an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload of monomethyl auristatin E (MMAE), which is in Phase I clinical trial; CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFß expressed on cancer cells for the treatment of solid tumors; CRB-913, a peripherally restricted cannabinoid type-1 (CB1) receptor inverse agonist for the treatment of obesity. It has a licensing agreement with Jenrin Discovery, LLC to develop and commercialize the licensed products, including the Jenrin library of approximately 600 compounds, and multiple issued and pending patent filings. The company was incorporated in 2009 and is based in Norwood, Massachusetts.iTeos Therapeutics NASDAQ:ITOS$10.15 0.00 (0.00%) As of 08/29/2025iTeos Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery and development of a new generation of immuno-oncology therapeutics for people living with cancer. Its pipeline includes EOS-448, Inupadenant, and EOS-984. The company was founded by Michel Detheux in April 2012 and is headquartered in Watertown, MA. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 09/01 - 09/05 Lululemon Share Price Has Plenty of Room Left to Fall Why DocuSign Could Be a SaaS Value Play After Q2 Earnings Why Hedge Fund Elliott Bet $4B on Pepsi and Sees Over 50% Upside Palantir Insider Selling: Risk Signal or Normal Activity? Advanced Micro Devices' 2026 Forecasts Are Way Too Low Salesforce Stumbles, But Investors Eye a Major Comeback Buy the Dip? GitLab’s Bullish Case Outweighs the Bears Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
